OpenBrief
⌘K
Log in Sign up
What the picker changes
  • Top topics digest — the cards score the selected period against the prior 4 weeks.
  • 12-week heatmap & outlet matrix — show the 12 weeks ending at the selected week (they slide back with the picker, they aren’t a fixed snapshot).
  • Per-topic volume / alias drift — same 12-week trailing window, anchored on the selected period.
  • Coverage gap quadrant — scores the selected period against the 12 weeks before it (not including it).
  • Anomaly cards — only show alerts the detector fired during the selected period. Quiet weeks legitimately show none.
What stays as-is
  • Outlet orientation strip / lean colours — context-only, drawn from the last 12 weeks of activity regardless.
  • Co-occurrence graph — recent-activity anchored, not picker-driven.
  • Source & topic profiles — all-time data for the topic; the picker doesn’t affect them.
Rolling 7 days is a sliding live window for “current vibes”; switch to Weekly to compare specific weeks side-by-side.
Weekly Rolling 7 days
live window
Press topic

New Drug Application Process

1 articles · 1 aliases in press · peaked week of 31 May 2026 · first seen 2 Jun 2026

A new drug, daraxonrasib, has shown a significant breakthrough in treating advanced pancreatic cancer by doubling survival time and improving quality of life, with results from a 500-patient trial set to inform future regulatory submissions.

Coverage by outlet lean Methodology →

Stacked weekly counts; colour by editorial lean. Stuff and The Spinoff lean centre-left, NZ Herald centre-right, others centre.

Alias drift

How press outlets have named this topic, week by week.

Free account Create a free account to watch this topic — get alerted when framing shifts, when an MP adopts new language, or when discourse and press diverge. Create a free account Log in

Recent headlines

Most recent 1 articles linking to this topic.

Sample framings

Up to 12 framings spread across outlets. Each framing is the LLM's one-line characterisation of the article's editorial angle — not a quote.

odt Centre

regulatory path to global approval

Drug could double survival time: prof
1 Jun
Free account Create a free account to see every framing on this topic — plus alerts when framing shifts or an MP adopts new language. Create a free account Log in

Spotted something wrong on this page? Report a correction.